US2020148717A1PendingUtilityA1

Non-hormonal steroid modulators of nf-kappa beta for treatment of disease

74
Assignee: REVERAGEN BIOPHARMA INCPriority: Nov 29, 2011Filed: Sep 24, 2019Published: May 14, 2020
Est. expiryNov 29, 2031(~5.3 yrs left)· nominal 20-yr term from priority
Inventors:John M. MccallEric HoffmanKanneboyina NagarajuJesse Damsker
C07J 7/003A61K 31/58A61K 31/573A61P 19/02A61P 3/00A61P 3/10A61P 29/00
74
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to compounds and methods which may be useful as treatments of diseases.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 - 10 . (canceled) 
     
     
         11 . A method of reducing the symptoms of a disease chosen from vasculitis and myositis in a patient in need thereof, comprising the administration, to the patient, of a therapeutically effective amount of a compound having the structural formula: 
       
         
           
           
               
               
           
         
       
     
     
         12 . The method of  claim 11 , wherein the disease is vasculitis. 
     
     
         13 . The method of  claim 12 , wherein the vasculitis is chosen from Henoch-Schönlein purpura or polyarteritis nodosa. 
     
     
         14 . The method of  claim 11 , wherein the disease is myositis. 
     
     
         15 . The method of  claim 14 , wherein the myositis is chosen from polymyositis and dermatomyositis. 
     
     
         16 . The method of  claim 11 , wherein the symptom is fever. 
     
     
         17 . The method of  claim 11 , wherein the symptom is headache. 
     
     
         18 . The method of  claim 11 , wherein the symptom is pain. 
     
     
         19 . The method of  claim 11 , wherein the symptom is inflammation. 
     
     
         20 . The method of  claim 19 , wherein the inflammation is in the lungs of the patient. 
     
     
         21 . The method of  claim 11 , wherein the symptom is hypertension. 
     
     
         22 . The method of  claim 11 , wherein the symptom is heart disease. 
     
     
         23 . The method of  claim 11 , wherein the patient is an adult human. 
     
     
         24 . The method of  claim 11 , wherein the therapeutically effective amount of the compound is adjusted for the age of the patient. 
     
     
         25 . The method of  claim 11 , wherein the disease is dermatomyositis, and the therapeutically effective amount of the compound is adjusted for the age of the patient. 
     
     
         26 . The method of  claim 25 , wherein the symptom is one or more chosen from fever, headache, pain, inflammation, hypertension, and heart disease.

Join the waitlist — get patent alerts

Track US2020148717A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.